Pharmaceutical company stock surges by 5% following the acquisition of a ₹232 crore order for the supply of pharmaceutical products
Pharmaceutical company: stock surges by 5% One of the microcap pharmaceutical stocks specializes in researching, developing, manufacturing, and distributing high-quality pharmaceutical products, including B-lactam antibiotics and antiretroviral drugs. Recently, the stock surged to its 5 percent upper circuit after securing an order worth approximately Rs. 232 crore for the supply of in-demand pharmaceutical products.
Stock Price Movement
With a market capitalization of Rs. 895.96 crores, shares of Bharat Parenterals Limited’s stock surged up to 5 percent, reaching near the upper circuit of Rs. 1,337.65 per share on Wednesday, up from its previous closing price of Rs. 1,274 per share.
What Happened
Bharat Parenterals Limited (BPL) announced the receipt of an order worth $27 million (approximately Rs. 232 crores) for the supply of high-demand pharmaceutical products over the next 18-24 months. This marks the largest order the company has ever secured, signifying a significant milestone in its growth.
Based in Vadodara, Gujarat, the company is a leading manufacturer of injectable pharmaceutical formulations committed to providing affordable, high-quality healthcare solutions globally. Its strong production capacities and extensive portfolio in the injectables segment solidify its position as a leader in the global pharmaceutical market.
Products and Services
Bharat Parenterals Limited offers a range of healthcare products, including B-lactam antibiotics, antiretroviral drugs, cephalosporins, tablets, capsules, liquid orals, ointments, creams, and powdered injections, covering various therapeutic areas for effective treatment and care.
Recent Quarter Results
In the recent quarter, Bharat Parenterals Limited’s revenue increased from Rs. 60 crore in Q2 FY24 to Rs. 72 crore in Q2 FY25, representing a growth of 249.33 percent. However, the company’s net profit turned negative, decreasing from Rs. 2 crore in Q2 FY24
For more market insights, follow our blog.
Stay tuned for more updates and insights on the stock market! For more insights on investing in the Indian stock market, check out resource like ET, NSE India.
Disclaimer: This blog post is for informational purposes only and should not be considered financial advice. Investors should conduct thorough research and consult with a qualified financial advisor before making any investment decisions.